Two of the leading pharmaceutical industries, Ranbaxy Laboratories and Cipla announced an alliance to co-market Ranbaxy's once-a-day formulation of Ciprofloxacin. The formulation had recently received Drug Controller General of India's (DCGIs) approval for marketing in India. Ciproloxacin is a unique dosage form of the broad-spectrum antibiotic. The domestic market for ciprofloxacin is estimated to be around Rs 310 crore.
Ciprofloxacin is the most potent fluoroquinolone with the widest spectrum bactericidal activity. It is a broad spectrum antibiotic. Hence, Ciproflxacin is being extensively used for blind therapy of infections.
According to the company, the alliance with Cipla for ciprofloxacin will be a win-win situation for both companies, enabling to leverage its combined marketing prowess and extensive distribution network. Ranbaxy official said that the company is keen that the benefits of Ciprofloxacin in terms of convenience and better patient compliance should percolate to the maximum number of doctors and patients.
The company believes that the Ciprofloxacin agreement has strengthened the spirit of cooperation that was started a few years ago between Cipla and Ranbaxy. Together, both the company brands account for over 30 per cent of the Ciprofloxacin market in India.